Listed

Ernexa Therapeutics Inc.: Form 10-Q for the period ended Mar 31, 2014

Filed with the SEC on May 15, 2014 and accepted by EDGAR at May 15, 2014, 16:24 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2014-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Selling, general and administrative3 months2014-01-01 to 2014-03-31$4.4mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2014-01-01 to 2014-03-31−$654.0kus-gaap:OperatingIncomeLoss
Income tax3 months2014-01-01 to 2014-03-31$10.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2014-01-01 to 2014-03-31−$649.0kus-gaap:NetIncomeLoss
Diluted EPS3 months2014-01-01 to 2014-03-31−$0.01us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2014-01-01 to 2014-03-31−$204.0kus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Capital expenditure3 months2014-01-01 to 2014-03-31$572.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2014-03-31$4.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2014-03-31$7.8mus-gaap:AssetsCurrent
Total assetsAt period end2014-03-31$15.5mus-gaap:Assets
Current liabilitiesAt period end2014-03-31$4.6mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2014-03-31$7.0mus-gaap:Liabilities
Shareholders' equityAt period end2014-03-31$8.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001019687-14-001956. Last ingested by Listed: Nov 11, 2026, 02:49 ET. Listed shows no prices and gives no investment advice.